Certara Products - Simcyp Archives

Blog

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

With the release of the draft ICH M15 guidance, MIDD is no longer optional -…

CertaraJune 11, 2025

On-Demand Webinar

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…

CertaraMay 23, 2025

Webinar

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

CertaraMay 12, 2025

Blog

Essentials of Model-informed Drug Development in Oncology

Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…

CertaraMay 2, 2025

On-Demand Webinar

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…

CertaraApril 21, 2025

Case Study

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

GRIN Therapeutics, Inc., an affiliate of Neurvati Neurosciences, focuses on the research and development of…

CertaraApril 16, 2025

Press Coverage

FDA to phase out animal testing with AI and lab-based models

FDA aims to replace animal testing in drug development with AI and lab-based models, enhancing…

CertaraApril 11, 2025

On-Demand Webinar

Model-informed Formulation Development: Bridging Experimental Data and Mechanistic Modeling

Discover how predictive modeling and model-informed formulation development (MIFD) are accelerating drug development. Learn from…

CertaraApril 11, 2025

Blog

Write Quicker PBPK Reports with the Simcyp Report Assistant

April 11, 2025 Writing a report for PBPK models can be an onerous process, especially…

CertaraApril 11, 2025

Press Release

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

RADNOR, PA — April 1st, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraApril 1, 2025

Certara Products – Simcyp

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

Essentials of Model-informed Drug Development in Oncology

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

FDA to phase out animal testing with AI and lab-based models

Model-informed Formulation Development: Bridging Experimental Data and Mechanistic Modeling

Write Quicker PBPK Reports with the Simcyp Report Assistant

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Newsletter sign up

Quick links

Solutions

Contact